Top

23-11-2015 | Multiple myeloma | Article

Family history of hematologic malignancies and risk of multiple myeloma: differences by race and clinical features

Journal: Cancer Causes & Control

Authors: MaryAnn E. VanValkenburg, Gwendolyn I. Pruitt, Ilene K. Brill, Luciano Costa, Maryam Ehtsham, Ian T. Justement, Racquel D. Innis-Shelton, Donna Salzman, E. Shyam P. Reddy, Kelly N. Godby, Fady M. Mikhail, Andrew J. Carroll, Vishnu B. Reddy, Ralph D. Sanderson, Louis B. Justement, Paul W. Sanders, Elizabeth E. Brown

Publisher: Springer International Publishing

Abstract

Purpose

Multiple myeloma (MM) is the most common hematologic malignancy affecting Blacks in the USA, with standardized incidence rates that are twofold to threefold higher than Whites. The rationale for the disparity is unclear.

Methods

Using participants enrolled in the Molecular And Genetic Epidemiology study of myeloma (259 MM cases; 461 controls), we examined the risk of MM associated with family history of cancer, differences by race and among cases, defining clinical features. Risk estimates were calculated using odds ratios and corresponding 95% confidence intervals from logistic regression adjusted for confounders.

Results

Overall, MM risk in cases with relatives affected with any hematologic malignancy was significantly elevated compared to controls (OR 1.89, 95% CI 1.25–2.86). Myeloma risk associated with a family history of MM was higher than the risk associated with any hematologic malignancy (OR 3.75, 95% CI 1.75–8.05), and the effect was greater for Blacks (OR 20.9, 95% CI 2.59–168) than Whites (OR 2.04, 95% 0.83–5.04), among cases with early onset (≤60 years; OR 4.58, 95% CI 1.21–17.3) and with increasing numbers of affected relatives (p trend = 0.001). Overall, frequencies of end organ damage differed in cases with relatives affected with any hematologic malignancy and significantly more cases exhibited κ light chain restriction (OR 3.23, 95% CI 1.13–9.26).

Conclusions

The excess risk of MM observed in Blacks and the variation in clinical features observed in MM patients according to family history of hematologic malignancy may be attributed to a shared germline and environmental susceptibility.

Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873CrossRefPubMed

Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300CrossRefPubMed

Landgren O, Kyle RA, Pfeiffer RM et al (2009) Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113:5412–5417CrossRefPubMedPubMedCentral

Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM (2009) A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113:5418–5422CrossRefPubMedPubMedCentral

Kyle RA, Therneau TM, Rajkumar SV et al (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 346:564–569CrossRefPubMed

Greenberg AJ, Rajkumar SV, Vachon CM (2012) Familial monoclonal gammopathy of undetermined significance and multiple myeloma: epidemiology, risk factors, and biological characteristics. Blood 119:5359–5366CrossRefPubMedPubMedCentral

Landgren O, Gridley G, Turesson I et al (2006) Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107:904–906CrossRefPubMedPubMedCentral

Landgren O, Katzmann JA, Hsing AW et al (2007) Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 82:1468–1473CrossRefPubMed

Waxman AJ, Mink PJ, Devesa SS et al (2010) Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 116:5501–5506CrossRefPubMedPubMedCentral

10.

Horwitz LJ, Levy RN, Rosner F (1985) Multiple myeloma in three siblings. Arch Intern Med 145:1449–1450CrossRefPubMed

11.

Lynch HT, Thome SD (2009) Familial multiple myeloma. Blood 114:749–750CrossRefPubMed

12.

Lynch HT, Watson P, Tarantolo S et al (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23:685–693CrossRefPubMed

13.

Roddie PH, Dang R, Parker AC (1998) Multiple myeloma in three siblings. Clin Lab Haematol 20:191–193CrossRefPubMed

14.

Grosbois B, Jego P, Attal M et al (1999) Familial multiple myeloma: report of fifteen families. Br J Haematol 105:768–770CrossRefPubMed

15.

Hemminki K, Li X, Czene K (2004) Familial risk of cancer: data for clinical counseling and cancer genetics. Int J Cancer 108:109–114CrossRefPubMed

16.

Bourguet CC, Grufferman S, Delzell E, Delong ER, Cohen HJ (1985) Multiple myeloma and family history of cancer a case–control study. Cancer 56:2133–2139CrossRefPubMed

17.

Eriksson M, Hållberg B (1992) Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case–control study. Cancer Causes Control 3:63–67CrossRefPubMed

18.

Altieri A, Chen B, Bermejo JL, Castro F, Hemminki K (2006) Familial risks and temporal incidence trends of multiple myeloma. Eur J Cancer 42:1661–1670CrossRefPubMed

19.

Kristinsson SY, Björkholm M, Goldin LR et al (2009) Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125:2147–2150CrossRefPubMedPubMedCentral

20.

Brown LM, Linet MS, Greenberg RS et al (1999) Multiple myeloma and family history of cancer among blacks and whites in the US. Cancer 85:2385–2390CrossRefPubMed

21.

Rajkumar SV, Dimopoulos MA, Palumbo A et al (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538–e548CrossRefPubMed

22.

Greipp PR, San Miguel J, Durie BG et al (2005) International staging system for multiple myeloma. J Clin Oncol 23:3412–3420CrossRefPubMed

23.

Howard VJ, Cushman M, Pulley L et al (2005) The reasons for geographic and racial differences in stroke study: objectives and design. Neuroepidemiology 25:135–143CrossRefPubMed

24.

Simpson NK, Johnson CC, Ogden SL et al (2000) Recruitment strategies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: the first six years. Control Clin Trials 21:356S–378SCrossRefPubMed

25.

Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006) Reliability of self-reported family history of cancer in a large case–control study of lymphoma. J Natl Cancer Inst 98:61–68CrossRefPubMed

26.

Camp NJ, Werner TL, Cannon-Albright LA (2008) Familial myeloma. N Engl J Med 359:1734–1735CrossRefPubMed

27.

Altieri A, Bermejo JL, Hemminki K (2005) Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. Blood 106:668–672CrossRefPubMed

28.

Wang SS, Slager SL, Brennan P et al (2006) Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10,211 cases and 11,905 controls from the InterLymph Consortium. Blood 109:3479–3488CrossRefPubMed

29.

Broderick P, Chubb D, Johnson DC et al (2012) Common variation at 3p22. 1 and 7p15. 3 influences multiple myeloma risk. Nat Genet 44:58–61CrossRef

30.

Chubb D, Weinhold N, Broderick P et al (2013) Common variation at 3q26. 2, 6p21. 33, 17p11. 2 and 22q13. 1 influences multiple myeloma risk. Nat Genet 45:1221–1225CrossRefPubMed

31.

Weinhold N, Johnson DC, Chubb D et al (2013) The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. Nat Genet 45:522–525CrossRefPubMed

32.

Pottern LM, Gart JJ, Nam JM et al (1992) HLA and multiple myeloma among black and white men: evidence of a genetic association. CEBP 1:177–182

33.

Schoenfeld Y, Berliner S, Shaklai M, Gallant LA, Pinkhas J (1982) Familial multiple myeloma. A review of 37 families. Postgrad Med J 58:12–16CrossRef

34.

Brown LM, Gridley G, Check D, Landgren O (2008) Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. Blood 111:3388–3394CrossRefPubMedPubMedCentral

35.

Hemminki K, Liu X, Forsti A, Ji J, Sundquist J, Sundquist K (2012) Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma. J Hematol Oncol 5:59CrossRefPubMedPubMedCentral

36.

Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K, Goldin LR (2006) Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case–control study. Int J Cancer 118:3095–3098CrossRefPubMed

37.

Lindqvist EK, Goldin LR, Landgren O et al (2011) Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood 118:6284–6291CrossRefPubMedPubMedCentral

38.

McShane CM, Murray LJ, Landgren O et al (2014) Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review. CEBP 23:332–342

39.

Baris D, Brown LM, Silverman DT et al (2000) Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health 90:1277–1281CrossRefPubMedPubMedCentral

40.

Bjornsson HT, Cui H, Gius D, Fallin MD, Feinberg AP (2004) The new field of epigenomics: implications for cancer and other common disease research. Cold Spring Harb Symp Quant Biol 69:447–456CrossRefPubMed

41.

Bjornsson HT, Fallin MD, Feinberg AP (2004) An integrated epigenetic and genetic approach to common human disease. Trends Genet 20:350–358CrossRefPubMed

42.

Feinberg AP (2007) Phenotypic plasticity and the epigenetics of human disease. Nature 447:433–440CrossRefPubMed